Clinical HoldThe FDA placed a clinical hold on zelnecirnon trials due to a case of liver failure, leading to the closure of Phase 2 trials.
Equity DilutionGiven RAPT's slow enrollment coupled with higher OpEx, significant equity dilution may be necessary to pull through on successful phase 3s, and product approval may be pushed out into 2030.
Workforce ReductionRAPT announced a 40% workforce reduction following setbacks for zelnecirnon, indicating potential long-term resolution issues.